Last week CEO had an interview on Aus biz. Which hotcopprr won’t let me post
I thought, there were drugs that have treatments for mychardial ischemia like Ace inhibitors but they have very poor efficacy in this condition. We are the only drug in the world with this new cardiovascular indication that actually protects the heart in this condition. There are no competing early stage drugs for this. We own this 4 billion dollar market. Worth north of 60-70 cents very easily at this early stage development right now. Which that valuation still doesn’t put it in line with similar companies on TBI
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)